APA (7th ed.) Citation

MH, O., O, J., MA, D., AM, D., R, P., RJ, G., . . . KT, F. (2025). Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(1), 56. https://doi.org/10.1158/1078-0432.CCR-24-0036

Chicago Style (17th ed.) Citation

MH, O'Hara, et al. "Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 31, no. 1 (2025): 56. https://doi.org/10.1158/1078-0432.CCR-24-0036.

MLA (9th ed.) Citation

MH, O'Hara, et al. "Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 31, no. 1, 2025, p. 56, https://doi.org/10.1158/1078-0432.CCR-24-0036.